
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health is facing some concerns regarding their Q4 performance, as although they beat expectations, the means in which they achieved it may not be sustainable. Their Diagnostics segment margin was also disappointing, but they did receive strong results from NGENLA gross profit share payments, BARDA revenue, and royalty revenue. Despite these concerns, the company maintains a strong cash position with $369 million in cash and $344 million in debt, giving them flexibility for future growth and development.
Bears say
OPKO Health is facing challenges in their diagnostics segment, with the recent divestiture of oncology assets resulting in a $18.3 million operating loss in the first full quarter since the divestiture. Although they have seen growth in certain tests, the overall performance equates to an annualized adjusted EBITDA loss of over $33.5 million and a $50 million loss in terms of adjusted operating income, leading to doubts on their ability to achieve profitable growth in this segment by 2026. Additionally, the company's recent financial results have been below expectations and we see little reason for the stock to perform well in the near-term.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares